135 related articles for article (PubMed ID: 32565133)
1. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma.
Bellmunt Molins J; García-Donas Jiménez J; Valderrama BP; Virizuela Echaburu JA; Hernando-Polo S; Climent Durán MÁ; Villa-Guzmán JC; Arranz Arija JÁ; Ostiategui ML; Milagro NL; González-Del-Alba A; González BM; Díaz EG; Gauna DC; Santasusana MD; Herranz UA; Del Muro Solans XG; Pérez-Gracia JL; Vázquez JP; Morales-Barrera R; Pous AF
Clin Genitourin Cancer; 2020 Dec; 18(6):452-460. PubMed ID: 32565133
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
Bellmunt J; Théodore C; Demkov T; Komyakov B; Sengelov L; Daugaard G; Caty A; Carles J; Jagiello-Gruszfeld A; Karyakin O; Delgado FM; Hurteloup P; Winquist E; Morsli N; Salhi Y; Culine S; von der Maase H
J Clin Oncol; 2009 Sep; 27(27):4454-61. PubMed ID: 19687335
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
[TBL] [Abstract][Full Text] [Related]
6. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
[TBL] [Abstract][Full Text] [Related]
7. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
[TBL] [Abstract][Full Text] [Related]
8. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Grivas P; Park SH; Voog E; Caserta C; Gurney H; Bellmunt J; Kalofonos H; Ullén A; Loriot Y; Sridhar SS; Yamamoto Y; Petrylak DP; Sternberg CN; Gupta S; Huang B; Costa N; Laliberte RJ; di Pietro A; Valderrama BP; Powles T
Eur Urol; 2023 Jul; 84(1):95-108. PubMed ID: 37121850
[TBL] [Abstract][Full Text] [Related]
9. Vinflunine.
Frampton JE; Moen MD
Drugs; 2010 Jul; 70(10):1283-93. PubMed ID: 20568834
[TBL] [Abstract][Full Text] [Related]
10. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
[TBL] [Abstract][Full Text] [Related]
11. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Vignani F; Tambaro R; De Giorgi U; Giannatempo P; Bimbatti D; Carella C; Stellato M; Atzori F; Aieta M; Masini C; Hamzaj A; Ermacora P; Veccia A; Scandurra G; Gamba T; Ignazzi G; Pignata S; Di Napoli M; Lolli C; Procopio G; Pierantoni F; Zonno A; Santini D; Di Maio M;
Eur Urol; 2023 Jan; 83(1):82-89. PubMed ID: 36216658
[TBL] [Abstract][Full Text] [Related]
12. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Powles T; Park SH; Caserta C; Valderrama BP; Gurney H; Ullén A; Loriot Y; Sridhar SS; Sternberg CN; Bellmunt J; Aragon-Ching JB; Wang J; Huang B; Laliberte RJ; di Pietro A; Grivas P
J Clin Oncol; 2023 Jul; 41(19):3486-3492. PubMed ID: 37071838
[No Abstract] [Full Text] [Related]
13. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
[TBL] [Abstract][Full Text] [Related]
14. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
15. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.
Harshman LC; Fougeray R; Choueiri TK; Schutz FA; Salhi Y; Rosenberg JE; Bellmunt J
Br J Cancer; 2013 Nov; 109(10):2548-53. PubMed ID: 24129239
[TBL] [Abstract][Full Text] [Related]
16. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
Palumbo R; Licata L; Sottotetti F; Tagliaferri B; Pozzi E; Teragni C; Quaquarini E; Bernardo A
Oncol Res Treat; 2018; 41(1-2):8-13. PubMed ID: 29402855
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
[TBL] [Abstract][Full Text] [Related]
18. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
Krajewski KM; Fougeray R; Bellmunt J; Pons F; Schutz FA; Rosenberg JE; Salhi Y; Choueiri TK
Eur J Cancer; 2012 Jul; 48(10):1495-502. PubMed ID: 22176867
[TBL] [Abstract][Full Text] [Related]
19. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
De Luca R; Profita G; Vella M; Cicero G
Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
[TBL] [Abstract][Full Text] [Related]
20. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]